课题基金 / 基金详情

Stimuli-responsive Delivery of Ectonucleotidase Inhibitors to Reprogram Immunometabolism in Head and Neck Cancer

Stimuli-responsive Delivery of Ectonucleotidase Inhibitors to Reprogram Immunometabolism in Head and Neck Cancer
刺激响应性递送外核苷酸酶抑制剂以重编程头颈癌的免疫代谢
批准号:
10589885
负责人:
Xin Ming
金额:
$17.75万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-04-01 至 2025-03-31

项目摘要

项目成果

Xin Ming的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 治疗诱导的癌症免疫受到肿瘤免疫抑制机制的限制 微环境(TME)。癌症治疗在以下过程中触发癌细胞释放ATP 免疫原性细胞死亡和胞外三磷酸腺苷在启动抗肿瘤免疫中起关键作用 作为危险信号。然而,细胞外的ATP很快被降解为免疫抑制腺苷,通过 CD39和CD73的协同酶活性,抑制抗癌免疫。全身性阻断这些 酶通常在正常组织中引起毒性,在那里它们保护宿主免受过度免疫激活的影响。 我们假设CD39/CD73抑制剂的刺激反应性递送重新编程免疫代谢 选择性地在TME中,导致有效和特异性的抗癌免疫而不产生免疫- 中介毒性。我们制备了含有苯基硼酸(PBA)的纳米颗粒(NPs),用于刺激- 反应灵敏的药物输送。CD39抑制剂ARL67156(ARL)是一种核苷酸类似物,被装载到NPs上 通过与PBA的互动。核苷酸药物可以通过活性氧从NPs中释放出来。 物种(ROS)介导的PBA降解。因此,我们进一步在纳米颗粒上负载了光敏剂IR700。 近红外光照射NPs产生ROS,引发NPs释放ARL。另一方面, 光动力疗法(PDT)的肿瘤细胞与纳米颗粒引起细胞外的ATP释放。发布的ARL 阻止ATP转化为腺苷,从而延长PDT释放的ATP的免疫原性 并防止腺苷介导的免疫抑制。免疫代谢格局的这种变化 TME在对免疫耐药的头颈部癌小鼠模型中导致了良好的肿瘤反应 检查站封锁。在这项提案中,我们将探索肿瘤交付后TME重新编程的机制 ARL(Aim 1)的抑制作用,并与其他癌症联合应用,增强CD39抑制的抗癌活性 免疫疗法治疗头颈部肿瘤的免疫抑制作用(目标2)。成功 该项目的实施将最终导致高度癌症特异性和多功能的递送系统 癌症免疫疗法。通过解决缺乏癌症特异性,发展NEXT的一个主要障碍- 随着新一代免疫治疗方案的问世,我们将为精确给药提供新的途径 免疫疗法。
英文摘要
Summary Therapy-induced cancer immunity is limited by immunosuppressive mechanisms posed by the tumor microenvironment (TME). Cancer therapy triggers ATP release from cancer cells during the course of immunogenic cell death and extracellular ATP plays a pivotal role in the initiation of antitumor immunity by acting as a danger signal. However, extracellular ATP is quickly degraded into immunosuppressive adenosine via the concerted enzymatic activities of CD39 and CD73, dampening anticancer immunity. Systemic blockage of these enzymes often causes toxicity in normal tissues, where they protect the host from excessive immune activation. We hypothesize that stimuli-responsive delivery of CD39/CD73 inhibitors reprograms immunometabolism selectively in the TME, leading to effective and specific anticancer immunity without generating immune- mediated toxicity. We have prepared phenylboronic acid (PBA)-containing nanoparticles (NPs) for stimuli- responsive drug delivery. CD39 inhibitor ARL67156 (ARL), a nucleotide analogue, was loaded to the NPs through the interaction with PBA. The nucleotide drug can be released from the NPs through reactive oxygen species (ROS)-mediated degradation of PBA. Thus, we further loaded a photosensitizer IR700 on the NPs. Irradiation of the NPs with NIR light produced ROS that triggered ARL release from the NPs. On the other hand, photodynamic therapy (PDT) of tumor cells with the NPs caused extracellular ATP release. The released ARL prevented conversion of ATP to adenosine, thereby extending the immunogenic actions by PDT-released ATP and preventing adenosine-mediated immunosuppression. This change of immunometabolism landscape in the TME led to excellent tumor response in a mouse model of head and neck cancers that is resistant to immune checkpoint blockade. In this proposal, we will explore the mechanisms for TME reprograming after tumor delivery of ARL (Aim 1), and will enhance anticancer activity of CD39 inhibition by combination with other cancer immunotherapy for treating immunosuppressive tumors of head and neck cancers (Aim 2). Successful implementation of this project will ultimately lead to highly cancer specific and versatile delivery systems for cancer immunotherapy. By addressing lack of cancer specificity, a main obstacle for the development of next- generation immunotherapeutic regimens, we will contribute to a novel approach for precision delivery of immunotherapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
Stimuli-responsive Delivery of Ectonucleotidase Inhibitors to Reprogram Immunometabolism in Head and Neck Cancer
Targeted Anchoring Ecto-enzyme on Cancer Cell Surface to Enhance Antibody Therapy in Breast Cancer
海外基金